EPKINLY epcoritamab

Drug Class

Bispecific CD20-directed CD3 T-cell engager

Mechanism

Binds CD20 on B-cells and CD3 on T-cells, inducing T-cell-mediated cytolytic activity against CD20-expressing lymphoma cells.

Approved Indication

Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.

What This Means For Patients

EPKINLY is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2023) — Sources

Pivotal Clinical Evidence

• EPCORE NHL-1 — Thieblemont et al., J Clin Oncol 2023 (NCT03625037) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly